Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
The Magic8 Pro is equipped with a 6.71" display that's almost looking like a downgrade compared to the Magic7 Pro's - after ...
Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...
The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering.This report tracks developments currently taking place ...
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ...
In the current study, published today in the journal Nature Biotechnology, Cheng and his colleagues created an exosome system ...
Researchers found that in mouse models (in a lab), SARS‑CoV‑2 mRNA vaccination triggered strong type I interferon signals, ...
The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback